Arkstone Introduces Interpretations of Skin Scrapings and Epidermal Samples

BOCA RATON, FL, August 17, 2023 — Arkstone Medical Solutions, the leading provider of laboratory infectious disease reporting and proactive antimicrobial stewardship, continues to spearhead innovation in infectious disease analysis. OneChoice, the cutting-edge system developed by Arkstone to provide physicians with patient-specific treatment recommendations, now includes interpretations of laboratory data taken via skin scrapings and epidermal samples. This advancement revolutionizes the management of superficial infections with a focus on topical antibiotic treatment.

Addressing Superficial Infections with Targeted Topical Antibiotics

Arkstone recognizes the critical need for precise and personalized care when addressing superficial infections, such as fungal infections and other skin conditions. By integrating data analysis from skin scrapings and epidermal samples into the OneChoice platform, Arkstone will provide healthcare providers with unparalleled insights into each patient’s condition. This enables them to make informed decisions regarding the most effective topical antibiotic treatments while minimizing systemic exposure to medications, thereby optimizing patient care and upholding antimicrobial stewardship principles.

Precision-Guided Patient Care: A Personalized Approach

Arkstone is dedicated to taking personalization in patient care to new heights. The latest innovation in interpreting skin scrapings and epidermal samples adds another layer of precision to the OneChoice reports. This new data analysis is incorporated into the proprietary decision engine, which leverages advanced artificial intelligence and deep insights into infectious diseases. By considering individual patient characteristics, including age, gender, diagnosis, and allergy profiles, healthcare providers can receive tailored recommendations that align with each patient’s unique needs. The focus on topical antibiotics emphasizes a more targeted approach to managing superficial infections effectively.

“We are thrilled to extend our OneChoice platform to include data interpretations from skin scrapings and epidermal samples,” says Dr. Ari Frenkel, infectious disease specialist, and Co-Founder & Chief Science Officer of Arkstone. “This innovation marks a significant advancement in precision-guided medicine, enabling healthcare providers to deliver targeted topical antibiotic treatments for superficial infections while adhering to antimicrobial stewardship principles.”